UNSPSC 51434400: Antihypertensive terpenes

Antihypertensive drugs made from a class of compounds composed of repeating 5-carbon units of hemiterpenes.

UNSPSC 51434400 Antihypertensive terpenes, a Class code, does not align with the state and local procurement activity currently tagged under it. The recent opportunities show state and local bodies soliciting emergency medications, generic pharmaceuticals, and direct-to-manufacturer prescription programs — none of which involve antihypertensive terpenes or botanical extract compounds that the code nominally describes. The City of Tampa's sealed-bid procurement (26P00188) seeks Advanced Life Support Medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802) targets generic multi-source pharmaceuticals and OTC products through established wholesaler channels; and the Texas Health and Human Services Commission RFI (HHS0017013) explores direct-to-manufacturer prescription fulfillment models for state pharmacy benefit programs. These solicitations represent mainstream pharmaceutical procurement, not specialized botanical or terpene-based therapeutics.

The issuing bodies span state agencies (Texas HHS, Minnesota Department of Administration), cities (Tampa), and cooperative purchasing consortia (MMCAP), but the mismatch between the code's stated scope and the actual work being bought suggests that this code sees little relevant recent state and local activity. The Tampa bid, due April 8, 2026, carries an estimated value of $40,000 and includes a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount; the MMCAP RFP, due March 26, 2026, covers two-year contracts for pharmaceuticals across multiple states with a 3 percent administrative fee on all purchases; and the Texas RFI represents early-stage market intelligence gathering rather than a formal competitive procurement. Without evidence of state and local buyers actually soliciting antihypertensive terpenes or botanical compounds under this code, the category should be watched only if your firm's portfolio includes mainstream emergency or generic pharmaceutical supply — not as a botanical-medicine opportunity.